Pilot Study Comparison of Combigan BID vs Simbrinza TID in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension

Trial Profile

Pilot Study Comparison of Combigan BID vs Simbrinza TID in Subjects Currently Treated With Latanoprost For Open-Angle Glaucoma or Ocular Hypertension

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 28 Feb 2017

At a glance

  • Drugs Brimonidine/timolol (Primary) ; Brimonidine/brinzolamide
  • Indications Ocular hypertension; Open-angle glaucoma
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Feb 2017 Planned number of patients changed from 40 to 43.
    • 20 Feb 2017 Planned End Date changed from 1 Oct 2015 to 1 Sep 2017.
    • 20 Feb 2017 Planned primary completion date changed from 1 Jul 2015 to 1 Sep 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top